The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study.


Journal

The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355

Informations de publication

Date de publication:
04 2021
Historique:
received: 30 10 2020
revised: 18 01 2021
accepted: 22 01 2021
pubmed: 23 2 2021
medline: 16 4 2021
entrez: 22 2 2021
Statut: ppublish

Résumé

During the COVID-19 pandemic, men who have sex with men (MSM) in the USA have reported similar or fewer sexual partners and reduced HIV testing and care access compared with before the pandemic. Pre-exposure prophylaxis (PrEP) use has also declined. We aimed to quantify the potential effect of COVID-19 on HIV incidence and HIV-related mortality among US MSM. We used a calibrated, deterministic, compartmental HIV transmission model for MSM in Baltimore (MD, USA) and available data on COVID-19-related disruptions to HIV services to predict effects of reductions in sexual partners (0%, 25%, 50%), condom use (5%), HIV testing (20%), viral suppression (10%), PrEP initiations (72%), PrEP adherence (9%), and antiretroviral therapy (ART) initiations (50%). In our main analysis, we modelled disruptions due to COVID-19 starting Jan 1, 2020, and lasting 6 months. We estimated the median change in cumulative new HIV infections and HIV-related deaths among MSM over 1 and 5 years, compared with a base case scenario without COVID-19-related disruptions. A 25% reduction in sexual partners for 6 months among MSM in Baltimore, without HIV service changes, could reduce new HIV infections by median 12·2% (95% credible interval 11·7 to 12·8) over 1 year and median 3·0% (2·6 to 3·4) over 5 years. In the absence of changes in sexual behaviour, the 6-month estimated reductions in condom use, HIV testing, viral suppression, PrEP initiations, PrEP adherence, and ART initiations combined are predicted to increase new HIV infections by median 10·5% (5·8 to 16·5) over 1 year, and by median 3·5% (2·1 to 5·4) over 5 years. Disruptions to ART initiations and viral suppression are estimated to substantially increase HIV-related deaths (ART initiations by median 1·7% [0·8 to 3·2], viral suppression by median 9·5% [5·2 to 15·9]) over 1 year, with smaller proportional increases over 5 years. The other individual disruptions (to HIV testing, PrEP and condom use, PrEP initiation, and partner numbers) were estimated to have little effect on HIV-related deaths (<1% change over 1 or 5 years). A 25% reduction in sexual partnerships is estimated to offset the effect of the combined service disruptions on new HIV infections (change over 1 year: median -3·9% [-7·4 to 1·0]; over 5 years: median 0·0% [-0·9 to 1·4]), but not on HIV deaths (change over 1 year: 11·0% [6·2 to 17·7]; over 5 years: 2·6% [1·5 to 4·3]). Maintaining access to ART and adherence support is of the utmost importance to maintain viral suppression and minimise excess HIV-related mortality due to COVID-19 restrictions in the USA, even if disruptions to services are accompanied by reductions in sexual partnerships. National Institutes of Health.

Sections du résumé

BACKGROUND
During the COVID-19 pandemic, men who have sex with men (MSM) in the USA have reported similar or fewer sexual partners and reduced HIV testing and care access compared with before the pandemic. Pre-exposure prophylaxis (PrEP) use has also declined. We aimed to quantify the potential effect of COVID-19 on HIV incidence and HIV-related mortality among US MSM.
METHODS
We used a calibrated, deterministic, compartmental HIV transmission model for MSM in Baltimore (MD, USA) and available data on COVID-19-related disruptions to HIV services to predict effects of reductions in sexual partners (0%, 25%, 50%), condom use (5%), HIV testing (20%), viral suppression (10%), PrEP initiations (72%), PrEP adherence (9%), and antiretroviral therapy (ART) initiations (50%). In our main analysis, we modelled disruptions due to COVID-19 starting Jan 1, 2020, and lasting 6 months. We estimated the median change in cumulative new HIV infections and HIV-related deaths among MSM over 1 and 5 years, compared with a base case scenario without COVID-19-related disruptions.
FINDINGS
A 25% reduction in sexual partners for 6 months among MSM in Baltimore, without HIV service changes, could reduce new HIV infections by median 12·2% (95% credible interval 11·7 to 12·8) over 1 year and median 3·0% (2·6 to 3·4) over 5 years. In the absence of changes in sexual behaviour, the 6-month estimated reductions in condom use, HIV testing, viral suppression, PrEP initiations, PrEP adherence, and ART initiations combined are predicted to increase new HIV infections by median 10·5% (5·8 to 16·5) over 1 year, and by median 3·5% (2·1 to 5·4) over 5 years. Disruptions to ART initiations and viral suppression are estimated to substantially increase HIV-related deaths (ART initiations by median 1·7% [0·8 to 3·2], viral suppression by median 9·5% [5·2 to 15·9]) over 1 year, with smaller proportional increases over 5 years. The other individual disruptions (to HIV testing, PrEP and condom use, PrEP initiation, and partner numbers) were estimated to have little effect on HIV-related deaths (<1% change over 1 or 5 years). A 25% reduction in sexual partnerships is estimated to offset the effect of the combined service disruptions on new HIV infections (change over 1 year: median -3·9% [-7·4 to 1·0]; over 5 years: median 0·0% [-0·9 to 1·4]), but not on HIV deaths (change over 1 year: 11·0% [6·2 to 17·7]; over 5 years: 2·6% [1·5 to 4·3]).
INTERPRETATION
Maintaining access to ART and adherence support is of the utmost importance to maintain viral suppression and minimise excess HIV-related mortality due to COVID-19 restrictions in the USA, even if disruptions to services are accompanied by reductions in sexual partnerships.
FUNDING
National Institutes of Health.

Identifiants

pubmed: 33617783
pii: S2352-3018(21)00022-9
doi: 10.1016/S2352-3018(21)00022-9
pmc: PMC8045548
mid: NIHMS1684590
pii:
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e206-e215

Subventions

Organisme : Medical Research Council
ID : MC_PC_19012
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069412
Pays : United States
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

AIDS Behav. 2021 Jan;25(1):40-48
pubmed: 32876905
J Acquir Immune Defic Syndr. 2021 May 1;87(1):639-643
pubmed: 33512848
Sex Transm Dis. 2020 Jul;47(7):434-436
pubmed: 32520878
AIDS Behav. 2020 Jul;24(7):2013-2016
pubmed: 32300993
Lancet Glob Health. 2020 Sep;8(9):e1102-e1103
pubmed: 32673576
J Int AIDS Soc. 2019 Mar;22(3):e25246
pubmed: 30868739
Lancet HIV. 2020 May;7(5):e308-e309
pubmed: 32272084
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
Lancet HIV. 2020 Jun;7(6):e384-e385
pubmed: 32359421
J Infect Dis. 2021 Mar 29;223(6):1019-1028
pubmed: 33507308
J Acquir Immune Defic Syndr. 2021 May 1;87(1):644-651
pubmed: 33443963
MMWR Morb Mortal Wkly Rep. 2020 May 22;69(20):630-631
pubmed: 32437340
MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603
pubmed: 31298662
Sex Res Social Policy. 2021 Aug 20;:1-15
pubmed: 34457080
AIDS Behav. 2021 Feb;25(2):311-321
pubmed: 32654021
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
Clin Infect Dis. 2021 Oct 5;73(7):e1964-e1972
pubmed: 32905581
Drug Alcohol Depend. 2020 Nov 1;216:108260
pubmed: 32890975
AIDS Behav. 2020 Jul;24(7):2024-2032
pubmed: 32350773
AIDS. 2020 Dec 1;34(15):2328-2331
pubmed: 32910069
Open Forum Infect Dis. 2020 Jul 02;7(7):ofaa275
pubmed: 32704518
AIDS Behav. 2020 Oct;24(10):2770-2772
pubmed: 32382823
Clin Infect Dis. 2021 Jun 1;72(11):e828-e834
pubmed: 33045723
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089

Auteurs

Kate M Mitchell (KM)

MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK. Electronic address: kate.mitchell@imperial.ac.uk.

Dobromir Dimitrov (D)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Romain Silhol (R)

MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.

Lily Geidelberg (L)

MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.

Mia Moore (M)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Albert Liu (A)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Bridge HIV, Population Health Division, San Francisco Department of Public Health, San Francisco, CA, USA.

Chris Beyrer (C)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Kenneth H Mayer (KH)

The Fenway Institute, Fenway Health, Boston, MA, USA; Harvard Medical School and TC School of Public Health, Boston, MA, USA.

Stefan Baral (S)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Marie-Claude Boily (MC)

MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH